MoonLake Immunotherapeutics (MLTX) Competitors

Cipher Mining (NASDAQ:CIFR) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both mid-cap business services companies, but which is the better investment? We will compare the two companies based on the strength of their risk, community ranking, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

Does the MarketBeat Community believe in CIFR or MLTX?

MoonLake Immunotherapeutics received 8 more outperform votes than Cipher Mining when rated by MarketBeat users. However, 94.74% of users gave Cipher Mining an outperform vote while only 80.52% of users gave MoonLake Immunotherapeutics an outperform vote.

Company	Underperform	Outperform
Cipher Mining	Outperform Votes 54 94.74%	Underperform Votes 3 5.26%
MoonLake Immunotherapeutics	Outperform Votes 62 80.52%	Underperform Votes 15 19.48%

Does the media refer more to CIFR or MLTX?

In the previous week, Cipher Mining had 1 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 9 mentions for Cipher Mining and 8 mentions for MoonLake Immunotherapeutics. Cipher Mining's average media sentiment score of 0.76 beat MoonLake Immunotherapeutics' score of 0.35 indicating that Cipher Mining is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cipher Mining	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MoonLake Immunotherapeutics	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has preferable valuation and earnings, CIFR or MLTX?

Cipher Mining has higher revenue and earnings than MoonLake Immunotherapeutics. Cipher Mining is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cipher Mining	$152.47M	14.85	-$25.78M	-$0.13	-50.08
MoonLake Immunotherapeutics	N/A	N/A	-$36.01M	-$1.29	-38.62

Do analysts prefer CIFR or MLTX?

Cipher Mining currently has a consensus target price of $7.72, suggesting a potential upside of 18.57%. MoonLake Immunotherapeutics has a consensus target price of $79.00, suggesting a potential upside of 58.57%. Given MoonLake Immunotherapeutics' higher possible upside, analysts plainly believe MoonLake Immunotherapeutics is more favorable than Cipher Mining.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cipher Mining	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20
MoonLake Immunotherapeutics	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.90

Is CIFR or MLTX more profitable?

MoonLake Immunotherapeutics has a net margin of 0.00% compared to Cipher Mining's net margin of -33.39%. Cipher Mining's return on equity of -8.29% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cipher Mining	-33.39%	-8.29%	-7.29%
MoonLake Immunotherapeutics	N/A	-15.54%	-15.09%

Do institutionals and insiders hold more shares of CIFR or MLTX?

12.3% of Cipher Mining shares are owned by institutional investors. Comparatively, 93.8% of MoonLake Immunotherapeutics shares are owned by institutional investors. 2.3% of Cipher Mining shares are owned by insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Which has more risk & volatility, CIFR or MLTX?

Cipher Mining has a beta of 2.18, meaning that its share price is 118% more volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500.

Summary

Cipher Mining beats MoonLake Immunotherapeutics on 12 of the 18 factors compared between the two stocks.